DMACDiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinan…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete. | ||
 All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy DiaMedica Therapeutics (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... DMAC reports statistically significant blood pressure reductions in late-onset preeclampsia, progresses FGR study, and maintains cash runway through 2027 despite increased R&D spending. | ||
 DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary Moby summary of DiaMedica Therapeutics Inc.'s Q2 2026 earnings call | ||
 DiaMedica Therapeutics Q2 Earnings Call Highlights DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027. President and Chief Executive Offi | ||
 DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential 1 Main Capital, a boutique investment firm, recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. 1 Main Capital Partners returned 15.0% in Q2 2026, compared to 15.2% and 21.6% for the S&P 500 (SPX) and Russell 2000 (RTY), respectively. SPX and RTY delivered their best performance since 2026 […] | IInsider Monkey | |